Clinical TrialJun 1, 2026, 10:03 AM
Legend Biotech Presents LB2102 & CARVYKTI Data at ASCO 2026
AI Summary
Legend Biotech presented first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC), at ASCO 2026. The data showed early evidence of clinical activity with an objective response rate of 20% and a manageable safety profile. Additionally, new analyses from the CARTITUDE program reinforced the durable efficacy and consistent safety profile of CARVYKTI ® (ciltacabtagene autoleucel) in multiple myeloma, which has now treated over 10,000 patients globally.
Key Highlights
- LB2102 showed an Objective Response Rate (ORR) of 20% (4/20) and Disease Control Rate (DCR) of 70% (14/20) in solid tumors.
- At higher dose levels (DL ">=" 3), LB2102 achieved an ORR of 28.6% and DCR of 78.6%.
- Median duration of disease control for LB2102 was 6.1 months, with median duration of response at 6.5 months.
- LB2102 demonstrated a manageable safety profile with 30% CRS (all Grade ">=" 2) and 15% ICANS (two Grade 1, one Grade 3).
- New CARVYKTI ® data from CARTITUDE-4 showed 30-month OS rates >85% in high-risk and standard-risk patients.
- CARVYKTI ® showed a low incidence (1.2%) of IEC-associated enterocolitis in a multi-study analysis.
- CARVYKTI ® is commercially available in 18 countries and has treated over 10,000 patients.
- Legend Biotech Ireland licensed DLL3-targeted CAR-T therapies, including LB2102, to Novartis Pharma AG in November 2023.
Price Impact
More from LEGN